Miahelsa Holdings Corporation Stocks

¥ 1199Last Updated 18.03.2026

Issuer Rating

3/7

Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

¥ 20.60M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
¥ 1199
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Modest margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Miahelsa Holdings Corporation engages in the operation of pharmaceutical, childcare, and nursing care businesses in Japan. The company operates dispensing pharmacies and provides home infusion therapy services. It also provides various nursing care services comprising in home care support, home-visit care, outpatient care, cohabitation care for dementia, home-visit nursing, visit bathing, small-scale multifunctional home care, support center, elderly welfare center, elderly with services homes for the elderly, and paid nursing homes with nursing care. In addition, the company operates health up center, welfare schools, nursery schools, and after school clubs. Further, the company is involved in the wholesale of food ingredients for school lunch; and provision of meal delivery services. Miahelsa Holdings Corporation was founded in 1966 and is headquartered in Tokyo, Japan.

Company Valuation

Fairly valued
4/7

Considering past and projected metrics, the stock is neither 'expensive' nor 'cheap' compared to its peers. In particular, the stock is overpriced on P/E, 'cheap' on EV/E

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks